摘要
目的评估重组人干扰素α2b喷雾剂(远策素喷雾剂)预防SARS等常见呼吸道病毒感染的效果。方法研究对象共14391人,用药剂量为90万IU/次,每日2次,连用5d,未次用药后15d取血,或用药前和用药3周后采取双份血清。采用随机、对照方法检测血清抗SARSCoVIgG抗体;采用双盲、随机、安慰剂对照方法测定血清抗常见呼吸道病毒(B型流感病毒、副流感病毒1～3型,呼吸道合胞病毒及腺病毒3、7型)的血清IgM抗体。结果两次实验中,干扰素组血清SARS病毒IgG抗体阳性率均较试验组高,但差异无统计学意义(P>0.05)。但用药组应用干扰素后副流感病毒1～3型,B型流感病毒,腺病毒3、7型和呼吸道合胞病毒IgM抗体阳性率(依次为6.45%、4.52%、4.30%和17.20%)均低于对照组(依次为19.40%、13.60%、7.12%和25.62%)。其中副流感病毒、B型流感病毒、腺病毒3种病毒IgM抗体阳性率差异均有统计学意义(P<0.01)。结论应用远策素喷雾剂鼻和咽部喷雾能不同程度地降低用药人群常见呼吸道病毒的感染率。
Objective To study the preventive effect of recombinant human interferon α-2b for nasal spray against SARS and other common respiratory viral infections by serum-epidemiological method, Methods A randomized, placebo-controlled, double-blind field trial study in populations with 14391 persons from SARS prevalent cities or provinces in China during May-Jun, 2003 and Dec-Apr, 2004. Interferon α-2b was given twice per day, once 9 × 10^5 IU by nasal spray for 5 days. Serum samples were taken at 15 days after last administration, Serological tests included SARS IgG antibody and IgM antibodies against influenza B, parainfleunza virus types 1-3, adenovirus type 3, 7 and respiratory, syncytial virus by using commercial ELISA kits, Results No statistically significant difference in serum SARS IgG antibody positive tale was found between the interferon and eontrol groups among 2757 serum samples. On the other hand, after using interferon, all four respiratory viruses （parainfluenza virus types 1-3; influenza B, adenovirus types 3, 7 and respiratory syncytial virus） in interferon group had lower IgM antibody positive rates than those in control group, Among them there were statistically significanl differences between the interferon and control groups for parainfluenza virus, influenza B and adenovirus. The preventive efficacy of interferon against four respiratory viruses was different, from high In low, the rank was Flu B（66.76% ）, parainfluenza types 1-3 （ 66, 75% ） , RSV （ 39. 61% ） and adenovierus （ 32. 86% ） , The average preventi efficacy was 50.27%, Conclusion The recombinant human interferon α-2b for nasal spray could decrease the rates of common respiratory viruses infection in the selected population.
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
北大核心
2005年第3期216-219,共4页
Chinese Journal of Experimental and Clinical Virology
基金
国家863计划资助(2003AA208206
2003AA208209)
